Recruiting
Enhancing Digitally Delivered Diabetes Education With Real-Time CGM
The current research study will add continuous glucose monitoring devices to the evidence-based text messaging diabetes education program for patients with type 2 diabetes for 6 months. Results on the effectiveness of this intervention will be compared for non-insulin using patients.
ClinicalTrials.gov IDNCT06296550
PhaseNA
Enrollment140
SponsorScripps Whittier Diabetes Institute
Age18 Years
SexALL
Conditions studied
Diabetes Type 2
About this study
The current research study will add continuous glucose monitoring devices to the evidence-based text messaging diabetes education program for patients with type 2 diabetes for 6 months. Results on the effectiveness of this intervention will be compared for non-insulin using patients.
Interventions
- Other: Dulce Digital Text Messaging Intervention — Text-based education support program: * Participants will receive text messages about diabetes and how to take care of diabetes and health. Participants will receive 2-3 messages every day for first 3 months, and then will slowly decrease over the last 3-months. * Participants will also receive text messages that will ask them to test their blood sugar and text back blood sugar reading.
- Other: CGM Device — Participants will be provided continuous glucose monitors (Dexcom G7) to actively monitor blood glucose for the entire duration of this study (i.e., one new device every 10 days for a total of 18 devices to last up to 6 months). In addition, participants will attend an information session (group or individual; in-person or virtual) that will provide instructions on using continuous glucose monitors.
Primary outcomes
- HbA1c (6 months)
Eligibility information
Inclusion Criteria:
* Diagnosed with type 2 diabetes
* Are not currently using a CGM
* Are not using insulin therapies
* Speak English, Spanish or Arabic
* Have A1c between 7.5% and 12.0% in last 90 days
* Have a cellphone that can receive/send text messages and counts steps
Exclusion Criteria:
* Are using insulin therapies
* Are pregnant
* Are currently using a CGM
* Are currently participating in another diabetes-related study
Study locations
- Scripps Whittier Diabetes Institute, San Diego, California 92037 United States
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.